Poly (adp-ribose) polymerase inhibitors: recent advances and future development
Details
Publication Year 2015-04-20, Volume 33, Issue #12, Page 1397-406
Journal Title
J Clin Oncol
Publication Type
Journal Article
Abstract
Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease. Consistent with preclinical studies, ovarian cancers and a number of other solid tumor types occurring in patients with deleterious germline mutations in BRCA1 or BRCA2 seem to be particularly sensitive. However, it is also becoming clear that germline BRCA1/2 mutations are neither necessary nor sufficient for patients to derive benefit from PARP inhibitors. We provide an update on PARP inhibitor clinical development, describe recent advances in our understanding of PARP inhibitor mechanism of action, and discuss current issues in the development of these agents.
Publisher
American Society of Clinical Oncology
WEHI Research Division(s)
Stem Cells And Cancer
PubMed ID
25779564
NHMRC Grants
NHMRC/1062702
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2015-05-20 10:11:25
Last Modified: 2016-04-20 12:02:04
An error has occurred. This application may no longer respond until reloaded. Reload 🗙